Human Apolipoprotein E4 Domain Interaction
Open accessAbstract
Human apolipoprotein (apo) E contains an amino- and a carboxyl-terminal domain, which are connected by a hinge region (approximately residues 165 to 215). The interaction of the two domains has been suggested to be responsible for the apoE4-binding preference for very low density lipoproteins (VLDL). In the absence of this interaction in apoE3, the preference is for high density lipoproteins (HDL). To exclude the possibility that the interaction of apoE with other apolipoproteins on the native particles may contribute to the isoform-specific preferences, VLDL-like emulsion particles were incubated with apoE, and the lipid-bound apoE was separated from free apoE on a Superose 6 column. The apoE4 bound more effectively to these particles than did apoE3, indicating that the apoE4 preference for VLDL is due not to interactions with other apolipoproteins but to an intrinsic property of apoE4, likely related to domain interaction. Previously, arginine 61 was shown to be critical for the isoform preferences, suggesting that it interacted with an acidic residue(s) in the carboxyl terminus. Substitution of arginine 61 with lysine did not alter the preference of apoE4 for VLDL, demonstrating that a positive charge rather than a specific requirement for arginine is critical for domain interaction. To identify the acidic residue(s) in the carboxyl terminus interacting with arginine 61, the six acidic residues (244, 245, 255, 266, 270, and 271) in a region known to be important for both lipoprotein association and isoform-specific preferences were substituted individually with alanine in apoE4. Only substitution of glutamic acid 255 altered the preference of apoE4 from VLDL to HDL, indicating that this was the sole residue in the carboxyl terminus that interacts with arginine 61. The participation of the hinge region in domain interaction was examined with internal deletion mutants. Deletion of the residues 186-202 or 186-223, representing major portions of the hinge region, had no effect on the apoE4 preference for VLDL. This suggests that the hinge region may act as a spacer that connects the two domains. Further deletion into the carboxyl-terminal domain (to residue 244) results in a loss of apoE4 VLDL binding. These studies establish that interaction of arginine 61 and glutamic acid 255 mediates apoE4 domain interaction.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The arginine at position 112 in ApoE4 is predicted to promote an interaction between the N- and C-terminal domains (domain interaction) that is absent in ApoE3 and ApoE2.
“The arginine at position 112 in ApoE4 is predicted to promote an interaction between the N-and C-terminal domains (domain interaction) that is absent in ApoE3 and ApoE2 23,26,27 .”
From Utilizing a cell culture based novel cellular thermal shift assay to understand the isoform-dependent thermal stability of ApoE variants (2026) · cites this paper as [26]
Higher binding of apoE4 does not appear to result from the interaction between the N- and C-terminal domains in apoE4 because the apoE4 E255A mutant in which the domain interaction is disrupted still exhibited much higher binding than apoE3.
“Such higher binding of apoE4 does not appear to result from the interaction between the N- and C-terminal domains in apoE4 because the apoE4 E255A mutant in which the domain interaction is disrupted (48) still exhibited much higher binding than apoE3 (Figs. 8A and 8B).”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [48]
The citation lists haven’t been fetched yet
References 47 · Cited by 318
- Authors
- Dong, L.-M., & Weisgraber, K. H.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Weisgraber, Karl H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1996-08
- Volume
- 271
- Issue
- 32
- Pages
- 19053-19057
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2067160010
- Cited by
- 318
- References
- 47
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 8 · 2023: 8 · 2022: 12 · 2021: 8 · 2020: 7 · 2019: 6 · 2018: 7 · 2017: 15 · 2016: 12 · 2015: 6 · 2014: 13 · 2013: 11 · 2012: 13
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-41633, P01HL041633)
- Topics
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- APOE ε4, apolipoprotein E3, VLDL, high-density lipoprotein, hinge region, C-terminal domain, N-terminal domain, domain interactions, acidic residues, point mutations, deletion mutants
- MeSH terms
- Apolipoproteins E, Arginine, Humans, Lipoproteins, VLDL, Protein Binding, Mutagenesis, Site-Directed, Sequence Deletion, Glutamic Acid, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review